Coherus market cap
WebJan 9, 2024 · CHRS has a market cap of $777mn and a cash reserve of $286mn. In November, Coherus revised the guidance range of combined 2024 R&D and SG&A expenses from $375 - $395 million to a range of … WebMar 28, 2024 · On Friday 03/10/2024 the closing price of the Coherus BioSciences Inc share was $6.07 on NAS. Compared to the opening price on Friday 03/10/2024 on NAS of $6.25, this is a drop of 2.97%. Coherus ...
Coherus market cap
Did you know?
WebCoherus Biosciences Stock Price Today (NASDAQ: CHRS) Quote, Market Cap, Chart WallStreetZen Coherus Biosciences Inc Stock Add to Watchlist Overview Forecast Earnings Dividend Ownership $6.00 +0.10 (+1.69%) Updated Mar 24, 2024 1W - 1.32% 1M - 13.54% 3M + 5.45% 1Y - 53.45% CHRS Price $6.00 Fair Value Price $6.82 Market … WebAbout Coherus Immuno-oncology Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines Our approved products span multiple therapeutic areas including oncology, …
WebMar 17, 2024 · See the latest Coherus BioSciences Inc stock price (NASDAQ:CHRS), related news, valuation, dividends and more to help you make your investing decisions. WebJul 18, 2024 · Coherus BioSciences has set a goal of capturing at least 10% market share with every biosimilar product. That could yield meaningful growth in the years ahead. …
WebView the latest Coherus BioSciences Inc. (CHRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. CHRS Coherus BioSciences Inc. … WebMar 6, 2024 · Coherus BioSciences, Inc. provided earnings guidance for the year 2024 and 2024. For the year, the company expects significant topline revenue growth. ... Capitalization: 621 M 621 M-EV / Sales 2024: 3,12x: EV / Sales 2024: 1,61x: Nbr of Employees: 359: Free-Float: 89,9%: More Financials.
WebApr 12, 2024 · The average twelve-month price prediction for Coherus BioSciences is $16.50 with a high price target of $26.00 and a low price target of $11.00. Do Wall Street analysts like Coherus BioSciences more than its competitors? Analysts like Coherus BioSciences more than other Medical companies.
WebGlobeNewswire. Oct-29-21 04:12PM. Coherus BioSciences to Report Third Quarter 2024 Financial Results on November 8th. GlobeNewswire. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to … crimson vow special landsWebApr 10, 2024 · Coherus BioSciences currently has a consensus target price of $16.50, indicating a potential upside of 115.40%. Sutro Biopharma has a consensus target price of $17.33, indicating a potential ... crimson vow spoilers nov 4WebApr 9, 2024 · The stock has a market cap of $609.81 million, a P/E ratio of -2.04 and a beta of 0.95. Coherus BioSciences, Inc. has a 1-year low of $5.58 and a 1-year high of $14.11. budnik wheels center capsWebApr 10, 2024 · Coherus BioSciences has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 0.89, suggesting that its stock price is ... budnik steering wheel with ididit columnWebDec 20, 2024 · Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the United States, and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the ... budnik wheel coversWebCoherus BioSciences market cap history and chart from 2013 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the … budnik wheels craigslistWebThe global crypto market cap is $1.25T, a 2.17 % increase over the last day. Read More The total crypto market volume over the last 24 hours is $50.34B , which makes a 23.24 % increase. crimson vow spoilers wizards of the coast